Wang Wen-Xiang, Zhang Wen-Jing, Peng Zhi-Lan, Yang Kai-Xuan
Department of Obstetrics and Gynecology, West China Second Hospital, Sichuan University, Chengdu, China.
Sichuan Da Xue Xue Bao Yi Xue Ban. 2009 Sep;40(5):857-60.
To detect the expression of CDC6 and hMSH2 in cervical carcinoma, explore the correlation with clinical significance and pelvic lymph node metastases.
SP immunohistochemistry technique was used to detect the expression of CDC6 and hMSH2 in specimens of 70 cervical carcinoma, and 14 normal cervix. Correlation between the expression of CDC6, hMSH2 and the clinicopathologic factors of cervical carcinoma were statistically analyzed.
The rates of positive expression of CDC6 and hMSH2 were 70.0%, 54.3% in cervical carcinoma, and significantly higher than those in normal cervix (P=0.000, 0.006). The CDC6 expression rate was related to pathological subtype, FIGO stage, histological tumor grade, pelvic lymph node metastases (P<0.05). The hMSH2 expression rate was related to pathological subtype, FIGO stage and pelvic lymph node metastases (P<0.05), but did not associate with histological tumor grade. The expression of CDC6 was positively correlated with hMSH2 in cervical cancer (r(s)=0.338, P=0.004), meanwhile it was not correlated with hMSH2 in 19 patients with pelvic lymph node metastases.
CDC6 and hMSH2 play an important role in the invasion and metastasis of cervical carcinoma. CDC6 and hMSH2 may be useful for predicting prognosis of cervical carcinoma.
检测宫颈癌组织中细胞分裂周期蛋白6（CDC6）和人错配修复蛋白2（hMSH2）的表达，探讨其与临床意义及盆腔淋巴结转移的相关性。
采用免疫组织化学SP法检测70例宫颈癌组织及14例正常宫颈组织中CDC6和hMSH2的表达，并分析CDC6、hMSH2表达与宫颈癌临床病理因素的相关性。
宫颈癌组织中CDC6和hMSH2的阳性表达率分别为70.0%、54.3%，显著高于正常宫颈组织（P = 0.000，0.006）。CDC6表达率与病理类型、国际妇产科联盟（FIGO）分期、组织学肿瘤分级、盆腔淋巴结转移有关（P < 0.05）。hMSH2表达率与病理类型、FIGO分期及盆腔淋巴结转移有关（P < 0.05），但与组织学肿瘤分级无关。宫颈癌组织中CDC6表达与hMSH2呈正相关（r(s)=0.338，P = 0.004），而在19例盆腔淋巴结转移患者中CDC6与hMSH2无相关性。
CDC6和hMSH2在宫颈癌侵袭和转移中起重要作用，可能对预测宫颈癌预后有一定价值。
